Join our daily newsletter At The Bell to receive exclusive market insights
- Creso Pharma’s (CPH) Canadian-based subsidiary, Halucenex Life Sciences, administers the first dose of its synthetic psilocybin product in a phase two clinical trial
- The first of 20 participants received both doses of the Lucenex-branded drug, initially a 10-milligram dose, followed by a macrodose of 25 milligrams in a separate session
- The trial is assessing the efficacy of the drug on treatment-resistant PTSD, and the remaining patients will receive the same dosages at a rate of two patients per week
- Halucenex is also looking to amend the trial to investigate sleep disruption as one of the most impactful symptoms of PTSD
- Creso Pharma shares closed at 2.1 cents on Wednesday afternoon
Creso Pharma’s (CPH) Canadian-based subsidiary, Halucenex Life Sciences, has administered the first dose of its synthetic psilocybin product in a phase two clinical trial.
The trial is testing the efficacy of psilocybin, a hallucinogenic substance found in certain types of mushrooms, on treatment-resistant post-traumatic stress disorder (PTSD).
Twenty participants were recruited, all of which suffer from PTSD as well as other mental health conditions including anxiety and depression.
The first participant received both doses of the Lucenex branded drug — initially a microdose of 10 milligrams, followed by a macrodose of 25 milligrams in a separate session.
No adverse reactions were reported in the initial dose, which Halucenex’s CEO and Founder, Bill Fleming, said provided the company with confidence moving to the next phase.
“Administering first dosages of our 100-per-cent-owned and formulated synthetic psilocybin follows a considerable amount of work undertaken by Halucenex in the recent months and highlights the potential opportunity that the company has at hand,” Mr Fleming said.
The remaining patients will receive the same dosages at a rate of two patients per week.
Halucenex has also decided to amend its clinical trial to investigate sleep disruption as one of the most impactful symptoms of PTSD and to alter the clinical trial score requirement into the severe PTSD indication.
These changes are in progress, and the company will continue the trial in the interim, which is expected to wrap up in the second quarter of next year.
Once completed, and if successful, Halucenex has planned to complete an extensive review of the data generated.
At the same time, the company said it would conduct a review of product development opportunities, research and development initiatives and potential licensing agreements.
Creso Pharma shares closed at 2.1 cents on Wednesday afternoon.
